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GnRH Binding RNA and DNA Spiegelmers:
A Novel Approach toward GnRH Antagonism
using mirror-image L-DNA or L-RNA aptamers. Pre-
viously, it has been shown that the principles of recipro-
cal chiral substrate specificity, coupled to the in vitro
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Petra Burgstaller,1,7 and Sven Klussmann1,3 selection process, make it possible to generate L-oligo-
nucleotide ligands, so-called Spiegelmers, that are in-1NOXXON Pharma AG
Gustav-Meyer-Allee 25 sensitive to enzymatic degradation. Using in vitro selec-
tion, an oligonucleotide sequence that binds the syntheticD-13355 Berlin
2 Research Laboratories of Schering AG enantiomer of the target molecule, e.g., a D-peptide, is
isolated. Subsequently, the selected nucleic acid ligand13342 Berlin
Germany is chemically resynthesized in the enantiomeric L-con-
figuration. Following the principle of chiral inversion, this
Spiegelmer will bind to the physiological target with the
same affinity and specificity as the aptamer to its mirror-Summary
image target. This strategy has been used to identify
L-RNA ligands of arginine and adenosine and an L-DNAMirror-image oligonucleotide ligands (Spiegelmers)
that bind to the pharmacologically relevant target go- ligand of vasopressin [4–6].
We have identified DNA and RNA Spiegelmers thatnadotropin-releasing hormone I (GnRH) with high af-
finity and high specificity have been identified using bind to the peptide hormone gonadoliberin (gonadotro-
pin-releasing hormone, GnRH I) with high affinity andthe Spiegelmer technology. GnRH is a decapeptide
that plays an important role in mammalian reproduc- high specificity. GnRH is a decapeptide that is released
from neurons of the hypothalamus in a pulsative mannertion and sexual maturation and is associated with sev-
eral benign and malignant diseases. First, aptamers [7–9], binding to receptors on gonadotrophic cells of
the pituitary gland. GnRH triggers the secretion of thethat bind to D-GnRH with dissociation constants of
50–100 nM were isolated out of RNA and DNA libraries. gonadotropin-luteinizing hormone (LH) and follicle-stim-
ulating hormone (FSH) [10]. The gonadotropins stimulateThe respective enantiomers of the DNA and RNA ap-
tamers were synthesized, and their binding to L-GnRH the production of sexual steroids (estrogens, progester-
one, or testosterone), which regulate the maturation ofwas shown. These Spiegelmers bind to L-GnRH with
similar affinity to that of the corresponding aptamers reproductive and other target organs. In addition, sexual
hormones are involved in pathological states like endo-that bind to D-GnRH. We further demonstrated dose-
dependent inhibition of GnRH-induced Ca2 release in metriosis [11, 12] and uterine fibrosis [13, 14] as well as
in malignant tumors like breast and prostate cancer [15].Chinese hamster ovary cells that were stably trans-
fected with the human GnRH receptor. These tumors can be treated with GnRH analogs that
lead to an inactivation of gonadal steroid produc-
tion [16].Introduction
Using the Spiegelmer technology, we have been able
to generate GnRH binding L-RNA and L-DNA ligands.The technique of in vitro selection of combinatorial oligo-
nucleotide libraries has been used to isolate nucleic acid Both Spiegelmers specifically antagonize the response
to GnRH in cell culture and therefore demonstrate theirligands that recognize a wide range of target molecules
with affinities and specificities comparable with or even activity in vitro. Since lowering the concentration of free
GnRH by Spiegelmers would reduce the gonadotropinexcelling those of antibodies [1, 2]. Over the last years,
tremendous progress has been made in the field, and release and thus the production of the sexual hormones,
GnRH binding Spiegelmers can be envisioned for theit has been anticipated that these so-called aptamers
will rival antibodies in their applications as therapeutic treatment of benign and malign hormone-responding
tumors. Further possible applications include their useand diagnostic agents in the future [3].
However, the utility of oligonucleotide-based thera- as contraceptives and as gonadotropin-lowering drugs
in the context of in vitro fertilization [17].peutics is limited due to their susceptibility to nucleases
present in biological fluids. The Spiegelmer technology
provides an elegant way to circumvent this limitation
Results
3 Correspondence: sklussmann@noxxon.net
Isolation of D-GnRH Binding RNA and DNA Ligands4 Present address: Dade Behring Marburg GmbH, Postfach 1149,
Using the method of in vitro selection, we sought toD-35001 Marburg, Germany.
5 Present address: Bayer AG, Central Research Department, Bio- isolate both RNA and DNA ligands of D-GnRH from oligo-
physics, Building E 41, D-51368 Leverkusen, Germany. nucleotide libraries with an initial complexity of 1015 dif-
6 Present address: Degussa AG, CV-PH-BT, Rodenbacher Chaussee ferent RNA or ssDNA molecules, respectively. Each pop-
4, D-63457 Hanau-Wolfgang, Germany. ulation contained a central core of 60 completely7 Present address: NascaCell GmbH, Bahnhofstrasse 9-15, 82327
randomized positions. Affinity chromatography usingTutzing, Germany.
D-GnRH immobilized on thiol-modified sepharose was8 S.L. is no longer employed by NOXXON and does not have a present
address. employed to separate binding from nonbinding oligonu-
Chemistry & Biology
352
Table 1. Sequence Analysis of the Clones Obtained by RNA and DNA In Vitro Selection
(A) RNA Sequence of the Random Region
-G-CCGATG-CGTCTCCTAATTGATAGAAAGACTACTTGAGCCCTTAAATGAGGTTATGTGCA A10 59x
--------------------------------------------------------------G A01 6x
---------C----------------------------------------------------- A06 2x
-----------------A--------------------------------------------- B05 1x
-----T--------------------------------------------------------- B06 2x
A-------------------------------------------------------------- C12 1x
--C------C----------------------------------------------------- C02 1x
-------C------------------------------------------------------- D02 1x
-------------------------------------------------------------- E10 1x
---------------------------T----------------------------------- G02 1x
GTTGGGAAGGGGTATGACCGACAGTAGGCGTCCTGATCTCCTGCGGCCTACTCCAACGCC D03 2x
TCGTCGCTTGGCATACATCTCGAGCAATGATTCGTTGCAGATAACTGTGAGAGCATGGTGC B04 1x
GTCACGAATTTGGATTGTGGCTTGAGAGCGTCTGACTGCTTGTCTAGACAAACTGTCGCG D12 1x
AATTCGTTAACGGGTCTAATTCTAACTTACGGTAAGCCGGAGTCGAAATTAGGTTACGCG F01 1x
(B) DNA Sequence of the Random Region
GGACGGCGTGGTAGGCTCAGGCGATATGCACGTGTGGATCACCTACACTTTGCTTGGGTG S40 10x
TATGGGCTGGGCAAGGGCTGGACAACAGATCCGTAGCTGTGGTGGCTGGCATACTGTAGG S15 4x
CGATCGCCACCACATGATAATAGCTTGTGTGAGGTACCAAGTGCATCTGTCCGTGGA S09 15x
AAAAGGATATTCGGCGTGCACATGGCCTCTCGGAGAAGTGCAGGGGTGGGTGGGAGCGTT S20 5x
CAAGACGACGGACGAGGGGTTAGGGGATTGATAGTAATCTCGGATATCCCCTCAAGCTCA S03 10x
AGGGTGGGCTGGGGCTGGGCCGGGGGGCGTGAGCGGAAAGTGCGACACGTAGCCTTGCA S42 1x
GCAGCTGCTGAGAAGCGAGCGTGGTGACTGGGTAATGTAATGGGGAAGGGCTGTATGGTT S35 1x
TAGTGGGGACCCCAATCTGTAGATGCCCGTAACGGGCTGGGGNTNCTGACACGGCATGGT S10 1x
GAAACCACGGGGACCCGCAATTGTGGGATAGCTACGTTCACATCACGTCAGCTATAGT S04 1x
The triangle indicates a base deletion compared to clone A10, and the hyphens indicate base homology to clone A10. The numbers in the
second column show the frequency with which the respective sequence was found.
cleotides. D-GnRH binding molecules were eluted from was found 15 times, 2 sequences were found 10 times,
and 2 sequences occurred 4 and 5 times, respectively.the column by affinity competition with D-GnRH in solu-
tion and amplified by either RT/PCR and transcription Four sequences just occurred once. Computer-assisted
alignment of distinct sequences from the ssDNA selec-for the RNA selection or by PCR for the DNA selection,
respectively. For the DNA selection experiment, positive tion did not reveal any common motif based on primary
sequence conservation (see Table 1B).DNA strands were obtained from double-stranded PCR
products based on the use of a negative-strand PCR Using equilibrium dialysis, we screened the affinities
of individual sequences to D-GnRH from both RNA andprimer with an uncopyable tail [18]. The enriched oligo-
nucleotide population formed the starting pool for the DNA selections. Of the sequences identified from the
RNA selection, sequence A10, which accounted for thenext round of selection. After the second round of selec-
tion, a negative selection on underivatized resin was majority of the selected population, showed the highest
affinity to D-GnRH, with an equilibrium dissociation con-introduced to prevent the accumulation of nonspecific
column binding aptamers. The stringency of the selec- stant of KD  92  12 nM. Of the DNA ligands tested,
clone S42, which is unique among the selected mole-tion experiments was progressively increased by de-
creasing the ratio of target to nucleic acid. Affinity elution cules, bound to GnRH with an affinity significantly higher
than that of all other DNA binding sequences. The equi-with D-GnRH included long incubation times in order to
encourage the isolation of high-affinity aptamers with librium dissociation constant was found to be KD  55
7 nM for D-GnRH binding (data not shown).long off rates (see the Experimental Procedures).
Only 0.01% of the input RNA and ssDNA populations
was eluted with D-GnRH during the first selection cycle. Identification of Minimal Binding Domains
Based on the results obtained from the affinity screeningThe percentage of eluted RNA increased up to 20% in
the sixth round of selection and up to 13% in the eighth of individual RNA and DNA ligands, sequences A10
(RNA) and S42 (DNA) were chosen for further character-round for ssDNA. Oligonucleotides recovered from the
respective rounds were converted to dsDNA for cloning ization.
In order to determine the minimal sequence require-and sequencing.
Among the 80 clones of the RNA selection that were ments needed for D-GnRH binding, various truncated
and mutated fragments of both sequences were gener-sequenced, one sequence was found 59 times (A10, see
Table 1A). An additional 16 sequences differed from this ated, and their respective binding affinities to D-GnRH
were determined by equilibrium dialysis. In addition, en-parent sequence only by point mutations or by single
base insertions or deletions. Another five sequences did zymatic and chemical probing was carried out to evalu-
ate the secondary structure formed [19]. By combiningnot show any similarity to the parent sequence (see
Table 1A). the results of these experiments with secondary struc-
ture predictions using the Zuker mfold computer algo-Sequencing of 48 clones from round 8 of the ssDNA
selection revealed 9 different sequences. One sequence rithm (mfold Zuker 2.3 [20, 21], mfold Zuker 3.0 [22]),
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Figure 1. Sequence and Proposed Secondary Structure of the RNA Ligand
(A) Sequence of RNA clone A10. The defined primer binding sites are shown in bold. The 48-nt long binding core is underlined. Base
substitutions introduced for thermal stabilization of the RNA oligonucleotide are indicated with respect to their position in the original molecule
in the line below.
(B) Proposed secondary structure model of the 50-nt RNA oligonucleotide ligand.
we were able to effectively truncate the RNA and DNA probing), indicating a possible G-quartet-like structure
(data not shown). Combining these results with the dataaptamers to their minimal binding motifs.
The D-GnRH binding domain of the RNA aptamer con- obtained by secondary structure prediction, we pro-
posed the secondary structure model shown in Fig-sists of a 48 nucleotide-(nt) sequence formed by parts
of the original random region including three nucleotides ure 2B.
For further truncation of sequence S42, we deletedof the 3 primer binding site (Figure 1A). The secondary
structure model obtained from the RNA mfold program the bases A39–A52 and introduced a thermodynamically
stable GTAA loop closed by a G:C base pair. In addition,and the results from DMS and kethoxal probing and
enzymatic probing with nucleases S1 and T2 (data not the base pairs T3:A66 and A6:T63 were substituted by
G:C base pairs. In order to circumvent the problematicshown) suggest that the 48-nt D-GnRH binding ligand
forms a three-way helix junction with four unpaired nu- synthesis of four consecutive G nucleotides, the terminal
C:G base pair was inverted. The substitutions and dele-cleotides at the branching point. To increase the thermal
stability of the molecule, the A:U base pairs at the 5- tions led to a 60-nt aptamer (Figure 2C). We were not
able to further truncate the DNA ligand without signifi-and 3-terminal helical region of the 48-nt binding region
were changed to G:C base pairs without affecting affin- cant loss of binding affinity. The deletion of the unpaired
nucleotides C53 and T54, for example, led to a completeity. An additional G:C base pair was added to further
stabilize the secondary structure (Figure 1). Any at- loss of binding. In contrast to the thrombin aptamer [23,
24], a 15-nt DNA ligand that adopts a highly compacttempts to further truncate the molecule by either delet-
ing base pairs from the proposed stems or single bases G-quartet structure that is sufficient for binding, we ob-
served that the isolated G-quartet fold is not able tofrom unpaired regions (e.g., deletion of G44) resulted in
a complete loss of binding. bind to D-GnRH.
The 99-nt sequence of the DNA ligand S42 could ini-
tially be truncated to a 68-mer oligonucleotide by remov- Functional Characteristics of the RNA
and DNA Spiegelmersing parts of the original primer binding sites that were
not essential for binding to D-GnRH (Figure 2A). To inves- The mirror-image L-oligonucleotides corresponding to
the 50-nt RNA ligand and the 60-nt DNA ligand weretigate the potential secondary structure elements of the
68-mer DNA ligand, we used chemical probing on the generated by standard solid phase synthesis using en-
antiomeric nucleotides.bases of G, A, and T as well as enzymatic probing with
S1 nuclease (data not shown). The results suggest the The affinity of the DNA Spiegelmer to L-GnRH was
determined by equilibrium dialysis and compared to thepresence of a loop between bases 42 and 48 (see Figure
2B). G probing disclosed long stretches of protected data obtained for the 60-nt D-DNA ligand to D-GnRH.
As demonstrated in Figure 3A, both the DNA aptamer asguanosines, interrupted by unprotected pyrimidines (T
Chemistry & Biology
354
Figure 2. Sequence and Proposed Secondary Structure of the DNA Ligand
(A) Sequence of DNA clone S42. The defined primer binding sites are shown in bold. The 68-nt long binding core is underlined.
(B) Proposed secondary structure model of the truncated 68-nt DNA oligonucleotide ligand.
(C) Secondary structure model of the modified 60-nt DNA oligonucleotide ligand. Bases A39–A52 of the 68-nt long version of S42 were replaced
by a thermodynamically stable GTAA loop closed by a G:C base pair. In addition, base pairs T3:A66 and A6:T63 were substituted by G:C
base pairs. In order to simplify chemical synthesis, the terminal base pair C1:G68 was inverted.
well as the Spiegelmer bind to their respective peptide DNA Spiegelmer, their affinity to various neuroactive
peptides (see Table 2), both unrelated and related totargets with an equilibrium dissociation constant of
about 45 nM. GnRH, was determined by real-time kinetic measure-
ments using a Biacore 2000. The respective SpiegelmerSince reproducable determination of the equilibrium
dissociation constants of the 50-nt D- and L-RNA li- was biotinylated at its 5 end and immobilized on the
surface of a streptavidin-coated sensor chip. The inter-gands could not be obtained by equilibrium dialysis,
possibly because of diffusion of a fraction of the RNA action of bound Spiegelmers with increasing concentra-
tions (0.1–1000M) of the neuropeptides was monitoredthrough the membrane, isothermal calorimetry was used
for determination. Figures 3B and 3C show typical calori- in real-time with the change in the SPR response. For
analysis, the responses are scaled to the molar massmetric profiles of GnRH binding to the RNA oligonucleo-
tide ligands. The data sets satisfactorily fit with a one- of GnRH, and maximum binding of GnRH is set to 1
(100%). These responses are plotted versus the loga-site model after subtraction of a constant peak area to
correct for dilution effects. A total of 37.7  0.2% of the rithm of the concentration of analyte. As shown in Figure
4 for both Spiegelmers, saturation of binding can onlyD-RNA oligonucleotides have one binding site with an
equilibrium constant of 97  7 nM, while the remaining be observed in the case of GnRH at the peptide concen-
trations used in this assay. Both Spiegelmers are able tomolecules do not bind significantly. This corresponds to
a nominal equilibrium constant of 263 nM. The standard discriminate between GnRH and chicken LHRH, which
differ only in one amino acid (Arg8 is changed to Gln)reaction enthalpy of the interaction is H  1.8 kcal
mol1. by an affinity difference of 50-fold or greater for the RNA
Spiegelmer and a factor of 400 or greater for the DNAFor the L-RNA oligonucleotide, 46.1  0.3% of the
Spiegelmers have one binding site with an equilibrium Spiegelmer. While the DNA Spiegelmer binds to the
GnRH analog buserelin with at least 1000-fold reducedconstant of 87  9 nM, while the remaining molecules
do not bind significantly. This results in a nominal equi- affinity, the RNA Spiegelmer shows an at least 5-fold
reduced affinity to buserelin. No binding, even at highlibrium constant of 190 nM. The standard reaction en-
thalpy of the interaction is H  1.8 kcal mol1. concentrations, can be observed for the completely un-
related peptides vasopressin and oxytocin.To examine the binding specificity of the RNA and
GnRH Binding RNA and DNA Spiegelmers
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Figure 3. Affinity of the RNA and DNA Spie-
gelmers
(A) Equilibrium dissociation constants (KD) of
the DNA aptamer from D-GnRH (circles) and
the corresponding Spiegelmer from L-GnRH
(squares) determined by equilibrium dialysis.
The data was fitted assuming a 1:1 binding
process: 100%  [c]/(Kd  [c]).
(B) Calorimetric profile of the RNA aptamer
binding to D-GnRH. A total of 37.7  0.2% of
the RNA molecules have one binding site with
an equilibrium constant of 97  7 nM; the
remaining molecules do not bind signifi-
cantly. This corresponds to a nominal equilib-
rium constant of 263 nM.
(C) Calorimetric profile of the RNA Spiegelmer
binding to L-GnRH. A total of 46.1  0.3% of
the RNA molecules have one binding site with
an equilibrium constant of 87  9 nM; the
other 53.9 % do not bind significantly. This
corresponds to a nominal equilibrium con-
stant of 190 nM.
Bioactivity of GnRH Spiegelmers Stimulation of the receptor by GnRH leads to Ca2 re-
lease [26], which was detected by the Ca2-sensitiveChinese hamster ovary (CHO) cells that were stably
transfected with the human GnRH receptor [25] were fluorescent dye Fluo-III. It could be shown that increas-
ing amounts of Spiegelmer prevent the docking of GnRHused to examine the ability of the candidate Spiegelmers
to its receptor, resulting in a decrease of Ca2 release.to inhibit the binding of GnRH to its cell surface receptor.
Doses of 0.01–1.0 M of the RNA or DNA Spiegelmer,
respectively, resulted in a sigmoidal dose-response
curve showing the antagonistic activity of both Spie-Table 2. Sequence of the Neuroactive Peptides Used for
Determining the Specificity of the RNA and DNA Spiegelmer gelmers (Figure 5). IC50 values were determined to be
about 200 nM for the RNA Spiegelmer and 50 nM forPeptide Amino Acid Sequence
the DNA Spiegelmer. The IC50 of both Spiegelmers corre-
GnRH (LHRH) PyrGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 lated with the respective equilibrium dissociation con-
Buserelin PyrGlu-His-Trp-Ser-Tyr-D-Ser-Leu-Arg-Pro-NHEt
stants to GnRH obtained by equilibrium dialysis and(Bu)
isothermic calorimetry.Chicken PyrGlu-His-Trp-Ser-Tyr-Gly-Leu-Gln-Pro-Gly-NH2
LHRH
Oxytocin H-Cys-Tyr-Ile-Glu-Asn-Cys-Pro-Leu-Gly-NH2 Discussion
Vasopressin H-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 Using the Spiegelmer technology, we have identified
D-GnRH binding oligonucleotide ligands from a combi-
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Figure 4. Specificity of the RNA and DNA Spiegelmers
Using a Biacore 2000, the interaction of the immobilized Spiegelmers with increasing amounts (0.1–1000 M) of various neuroactive peptides
was monitored in real-time by the change in the SPR response. For analysis, the responses are scaled to the molar mass of GnRH, and
maximum binding of GnRH is set to 1 (100%). The responses are plotted versus the logarithm of the concentration of analyte.
(A) The results for the RNA Spiegelmer.
(B) The results for the DNA Spiegelmer.
natorial RNA library as well as from a combinatorial DNA experiments that identified RNA and DNA ligands for
binding to the same target [27, 28], the selected RNAlibrary. Both starting populations had an initial complex-
ity of about 1015 different molecules. While the RNA se- and DNA variants show no similarities with each other
with respect to their primary sequence and proposedlection revealed only one major binding sequence, sev-
eral sequence solutions without any similarity regarding secondary structure. While it appears that the RNA and
DNA variants do not differ much in the complexity ofprimary and secondary structure elements were ob-
tained from the DNA selection. As anticipated, the affinit- the structures needed for binding to GnRH, it seems
that, at least in this case, DNA solutions are more com-ies to D-GnRH of individual sequences from both the
RNA and the DNA selection are similar due to the rela- mon than RNA solutions. These results are consistent
with findings from earlier publications [29].tively low selection pressure that was applied during the
selection experiments. As found in previous selection The oligonucleotide ligands selected for binding to
GnRH Binding RNA and DNA Spiegelmers
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Figure 5. Bioactivity of the RNA and DNA
Spiegelmers
Ca2 release in response to GnRH in the pres-
ence of RNA (red circles) and DNA (blue cir-
cles) Spiegelmers. RNA or DNA was preincu-
bated with GnRH for 20 min prior to addition
to the cells. The resulting final GnRH concen-
tration was 2  109 M. The sigmoidal dose-
response curve showed antagonistic activity
of both Spiegelmers, with an IC50 of 50 nM
for the DNA Spiegelmer and 200 nM for the
RNA Spiegelmer, respectively. The positive
control used in the assay was the GnRH an-
tagonist ZK 204859 (black circles).
D-GnRH display equilibrium dissocation constants in the nition is achieved can only be obtained by crystal struc-
ture analysis or NMR spectroscopic methods.range of 50–100 nM. While truncation of the RNA ligand
to a 50-mer resulted in an approximately 2-fold decrease Cell culture experiments carried out to determine the
ability of the RNA and DNA Spiegelmer to inhibit bindingof binding affinity, truncation of the best GnRH binding
DNA sequence to a 60-mer did not decrease binding of L-GnRH to its cell surface receptor resulted in IC50
values of 200 nM for the RNA Spiegelmer and 50 nMaffinity. These results clearly demonstrate that it is pos-
sible to isolate oligonucleotide ligands with high affinity for the DNA Spiegelmer. It was shown for the first time
that both RNA and DNA Spiegelmers can be employedfor a small peptide, even though the structure of the
peptide is flexible and presumably exists in an equilib- as inhibitors of a pharmacologically relevant target.
Since the selected Spiegelmers are directed against therium of multiple conformers. It is conceivable that the
Spiegelmers force the decapeptide into a stable confor- peptide hormone, they might circumvent the problem
of side effects that are displayed by other known GnRHmation, as was observed for the binding of the HIV-1
Rev peptide by the Rev-responsive element and a re- analogs that bind to the receptor. Agonists like buserelin
stimulate hormone secretion in the initial treatmentlated RNA aptamer obtained by in vitro selection [30].
With equilibrium dissociation constants of 45 and 180 phase (flare) by increasing LH and FSH release from the
pituitary gland, before they exert an inhibitory effect. ThenM, the Spiegelmers obtained in this study rank among
the oligonucleotides with the highest affinities for small GnRH receptor/signaling complex will be desensitized
only upon prolonged application. By contrast, the re-peptides selected so far. Dissociation constants of li-
gands to substance P were determined to be 190 nM lease of LH and FSH is expected to be suppressed
immediately upon the application of Spiegelmers.[31], while the RNA ligands selected for binding to the
16-mer ARM of HIV-1 Rev protein showed KD values of
19–36 nM [32]. In the case of the ARM peptide, the rather Significance
high affinity may partly be due to interactions between
the positively charged peptide and the negatively The Spiegelmer technology provides a unique ap-
proach to generate mirror-image oligonucleotide li-charged RNA molecules.
Both Spiegelmers show high specificity for GnRH, gands for use in therapeutic and diagnostic applica-
tions, circumventing the limitations of natural nucleicsince the exchange of a single amino acid (Arg8→ Gln)
results in a dramatic loss of binding affinity, as was acid ligands. We have identified mirror-image DNA and
RNA oligonucleotide ligands (Spiegelmers) binding toshown for chicken LHRH. Obviously, the interaction with
Arg8 plays a major role for the binding of both Spiegel- the peptide hormone L-GnRH with high affinity and
high specificity. By demonstrating the bioactivity ofmers to GnRH. However, the RNA Spiegelmer also rec-
ognizes the GnRH analog buserelin, albeit with reduced both the RNA and the DNA Spiegelmer as GnRH antag-
onists in cell culture, we show that DNA as well as RNAaffinity. In contrast, the DNA Spiegelmer shows signifi-
cant binding to buserelin only at the highest concentra- Spiegelmers can be envisioned for the application as
therapeutic agents.tion examined, corresponding to an at least 1000-fold
reduced affinity. Therefore, one can conclude that, in
Experimental Proceduresthe case of the DNA Spiegelmer, the structural and con-
formational differences caused by the introduction of
Materials
unnatural amino acids have a much greater effect on All oligonucleotides were synthesized at NOXXON Pharma AG using
binding than in the case of the RNA Spiegelmer. How- standard phosphoramidite chemistry. D-GnRH (all D[pyrGlu-His-Trp-
Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2] and D-GnRH-Cys (all D[pyrGlu-ever, detailed information regarding how specific recog-
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His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Cys-NH2]; PyrGlu  pyroglu- 40:1 was used. In the following rounds, the ratio was decreased
from 20:1, 10:1, and 5:1 (four times) to 1:1 for the last round oftamate  5-oxo-D-proline) that contained an additional cysteine at
the C terminus were synthesized by Jerini Biotools. L-GnRH was selection.
purchased from Bachem. All peptides were analyzed by HPLC (220
nm) and electrospray ionization mass spectroscopy (ESI-MS). The Equilibrium Dialysis
peptide purity was greater than 95%. 3H-labeling (at the tyrosin To determine the binding affinity of individual oligonucleotide li-
residue) was performed by Amersham Pharmacia. gands, equilibrium dialysis in microdialysis chambers was employed
Buserelin was purchased from Sigma Aldrich; chicken LHRH, oxy- [33]. 3H-labeled D- or L-GnRH (c  10 Ci/mmol) was equilibrated
tocin, and vasopressin were purchased from Bachem AG. with increasing amounts of oligonucleotide (100 nM–5 M) in selec-
tion buffer or DNA-selection buffer, respectively. The dialysis was
performed through a Spectra/Por cellulose ester membrane (Spec-Sepharose
trum) with a molecular weight cutoff of 8,000–10,000 Da. After 24Thiolsepharose 4B (Pharmacia) was derivatized with 10–100 M
hr of dialysis at RT, aliquots were withdrawn from each compart-D-GnRH-Cys according to the manufacturer’s protocol. The cou-
ment, and the radioactivity was measured by scintillation counting.pling efficiency was determined by reduction of the disulfide bonds
The fraction of bound oligonucleotide was calculated from thewith DTT, followed by quantification of the released D-GnRH-Cys
amount of bound GnRH determined by the difference in GnRH con-by HPLC analysis. Thiopropylsepharose 6B (Pharmacia) was deriva-
centration in the two chambers. The calculated relative activitiestized as described above and used for DNA selection.
were fitted with a nonlinear regression technique (GraFit, Version
4.0) by using a standard binding equation for a 1:1 stoichiometry:In Vitro Selection Procedure
100%  [c]/(Kd  [c]).A combinatorial RNA library of approximately 1015 different mole-
cules was obtained by the conversion of a synthetic ssDNA library
Isothermal Calorimetry(ssDNA pool: 3-CCCTTAAGCTCGAGGACTGT-N60-TAAGCTTCTG
Calorimetry experiments were carried out in degased DNA selectionCAGGTCGACT-5; forward-primer: 5-TTCTAATACGACTCACTA
buffer at 25	C with a stirring speed of 300 rpm. The measuring cellTAGGGAATTCGAGCTCCTGACA-3 [T7 promotor is underlined]; re-
was loaded with 8.8 M D- or L-RNA, respectively. The correspond-verse primer: 5-TCAGCTGGACGTCTTCGAAT-3) into a double-
ing GnRH solution (0.06 mM) was injected (one 3-l injection first,stranded DNA product and further T7 transcription to an RNA library
followed by 6-l injections) from a 250-l syringe over a time interval(3-CCCTTAAGCTCGAGGACTGT-N60-TAAGCTTCTGCAGGTCG
of 6 s, with 300 s between the injections to allow for completeACT-5). The copyable fraction of the pool was determined to be
equilibration and baseline recovery.23% by extension of trace-radiolabeled, negative-strand primer un-
der conditions of a single PCR cycle. The starting pool was initially
Biacore Analysislabeled with 
32P-UTP by T7 transcription.
For real-time kinetic measurements, a Biacore 2000 from BiacoreThe peptide-derivatized sepharose was equilibrated with 6 ml
AB was used. The interaction analysis was performed at 25	C. Dur-selection buffer (10 mM HEPES [pH 7.5], 137 mM NaCl, 2.7 mM KCl,
ing the whole assay, 20 mM Tris (pH 7.4), 137 mM NaCl, 5 mM KCl,2 mM CaCl2, 1 mM MgCl2, 0.005% Triton X-100). The RNA was
2 mM CaCl2, 1 mM MgCl2, 0.005% Triton X-100 was used as runningdissolved in ddH2O, heated (5 min/95	C), and cooled down in selec-
buffer.tion buffer to room temperature for 15 min before being applied to
The 5-biotinylated RNA and DNA Spiegelmer was immobilizedthe derivatized sepharose 4B column. For the first round, a D-GnRH
on a Sensor Chip SA from Biacore AB. To ensure the highest sensitiv-to RNA ratio of 10:1 was chosen. For the following rounds, the
ity, the sensor surfaces were pretreated with three 1-min injectionsselection pressure was raised by decreasing the ratio from 5:1,
of 1 M NaCl in 50 mM NaOH at a flow rate of 20l/min. Subsequently,4:1, 3:1, and 2:1 to 1:4 in the last round of selection. Nonbinding
a 200 nM solution of the RNA Spiegelmer was manually injectedoligonucleotides were removed by washing with 12 volumes of se-
with a flow rate of 5l/min through flow cell (fc) 2 until 1120 responselection buffer. GnRH binding RNA molecules were eluted with selec-
units (RU) were captured by the streptavidin surface. Comparably,tion buffer containing free D-GnRH. The first volume was passed
1230 RU of the biotinylated DNA Spiegelmer were immobilized onthrough the column and collected. During the following two elution
fc 3. Fc 1 was left with streptavidin only, to be used as a referencesteps, the affinity column was incubated end over end for 1 hr at
surface. After Spiegelmer immobilization, 0.1% Triton X-100 in 10RT with two volumes of binding buffer containing D-GnRH. Two more
mM sodiumacetat (pH 4.5) was injected in three 1-min pulses tovolumes were passed through and collected. The concentration of
wash off unbound oligonucleotides.free peptide was five times higher than the concentration of D-GnRH
The respective peptides were injected in varying concentrationsimmobilized on sepharose. After the second round of selection, a
(0.1–1000 M) in sequence over reference and Spiegelmer surfacesprecolumn with underivatized sepharose was used to prevent the
during 4 min at a flow rate of 5 l/min. Each cycle consisted of aaccumulation of nonspecific column binding aptamers. The precol-
2-min waiting period for the monitoring of baseline stability, a 4-minumn was washed with three volumes of selection buffer; the flow-
injection of peptide, a 5-min dissociation phase of bound peptide inthrough was collected and loaded onto the D-GnRH-derivatized
running buffer, and a regeneration step of sensor surfaces by thecolumn.
injection of 1 M NaCl in 0.02% Triton X-100 for 1 min at a flow rateAfter elution and collection of the D-GnRH binding oligonucleo-
of 20 l/min. Between each cycle, the system was idle for 3 min totides, each fraction was extracted with phenol/chloroform and fur-
maintain baseline stability. At the beginning and in a frequency ofther amplified by reverse transcription and PCR. The selected oligo-
15 cycles, an injection of water and running buffer was made tonucleotides formed the starting pool for the next cycle.
check for carryover effects.For the DNA selection, a ssDNA library (5-d[CCAAGCTTGCATG
Data obtained in the reference flow cell (fc 1) were subtractedCCTGCAG-N60-GGTACCGAGCTCGAATTCCC]-3) was generated
from those obtained in the Spiegelmer flow cell (fc 2 and fc 3). Forusing a negative-strand PCR primer with an uncopyable tail [18]. A
each sample, response values at 170 s after the end of injectionssDNA library generated by solid phase synthesis was amplified by
were extracted. The responses are scaled to the molar mass ofPCR using forward primer 5-(T)20-XCGGAATTCGAGCTCGGTACC-
GnRH, and maximum binding of GnRH is set to 1 (100%). These3 (X  Glen Research spacer phosphoramidite 18) and reverse
responses are plotted versus the logarithm of the concentration ofprimer 5-CCAAGCTTGCATGCCTGCAG-3. The smaller DNA tem-
analyte.plate (100 nt) was separated from the longer template (120 nt) by 8%
denaturing polyacrylamide gel electrophoresis. About 1015 different
ssDNA molecules of 32P-labeled ssDNA were used for the selection. Bioassay
The bioassay was performed at Schering AG. Chinese hamster ovaryD-GnRH-derivatized sepharose 6B was used for affinity chromatog-
raphy. The column was equilibrated with 6 ml DNA-selection buffer (CHO) cells expressing the human GnRH receptor were employed
[25]. A total of 5  104 cells per well were grown overnight at 37	C(20 mM Tris [pH 7.4], 137 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM
MgCl2, 0.005% Triton X-100). The selection procedure was carried on black, clear bottom well microtiter plates in Ham’s F12 medium.
The following day, dye loading was performed after removal of theout as described above. In the first round, a target to DNA ratio of
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medium (Ham’s F12 with 19.2 M Fluo-III, 0.04% pluronic acid, 4.8 of endometriosis and uterine fibromyoma. Minerva Ginecol. 45,
455–465.mM probenecid, 19 mM HEPES, 100 l/well) followed by 1 hr of
incubation at 37	C. The plate was washed three times with Hanks’ 15. Cook, T., and Sheridan, W.P. (2000). Development of GnRH
antagonists for prostate cancer: new approaches to treatment.solution (138 mM NaCl, 6 mM KCl, 1 mM MgSO4, 2 mM CaCl2, 1
mM Na2HPO4, 5.5 mM glucose, 20 mM HEPES [pH 7.5]) containing Oncologist 5, 162–168.
16. Leone, M., and Valenti, G. (1987). GnRH analogs: experimental5 mM probenecid and 0.2% BSA. The assay was performed by
incubating DNA or RNA Spiegelmers at a concentration of 1  and clinical review. Minerva Endocrinol. 12, 305–316.
17. Jennings, J.C., Moreland, K., and Peterson, C.M. (1996). In vitro106–108 M together with 2  109 M GnRH for 20 min before
adding the mixture to CHO cells. Binding of GnRH to its receptor fertilisation. A review of drug therapy and clinical management.
Drugs 52, 313–343.triggers the intracellular Ca2 release. The release is detected by
an intracellular fluorescence marker (Fluo-III) a few seconds after 18. Williams, K.P., and Bartel, D.P. (1995). PCR product with strands
of unequal length. Nucleic Acids Res. 23, 4220–4221.receptor stimulation. The signal is measured as a fluorescence peak
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